



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



(S)-Crizotinib

Item No. 31114

CAS Registry No.: 1374356-45-2
Formal Name: 3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
MF: C₂₁H₂₂Cl₂FN₅O
FW: 450.3
Purity: ≥98%
UV/Vis.: λ_{max}: 270 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(S)-Crizotinib is supplied as a solid. A stock solution may be made by dissolving the (S)-crizotinib in the solvent of choice, which should be purged with an inert gas. (S)-Crizotinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of (S)-crizotinib is approximately 0.5 mg/ml in ethanol and DMSO and approximately 5 mg/ml in DMF.

(S)-Crizotinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, (S)-crizotinib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. (S)-Crizotinib has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

(S)-Crizotinib is an inhibitor of muT homolog 1 (MTH1; IC₅₀ = 72 nM).¹ It is selective for MTH1 over a panel of 456 kinases at 1 μM. (S)-Crizotinib (30 μM) induces oxidative DNA damage and apoptosis in SGC-7901 and BGC-823 human gastric cancer cells.² It inhibits proliferation in a panel of 14 cancer cell lines expressing wild-type or various mutant forms of K-Ras and p53 (IC₅₀s = 0.52-7.4 μM).¹ (S)-Crizotinib (25 mg/kg, s.c.) reduces tumor growth in an SW480 mouse xenograft model.¹

References

1. Huber, K.V.M., Salah, E., Radic, B., *et al.* Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. *Nature* **508**(7495), 222-227 (2014).
2. Ji, J., Chen, W., Lian, W., *et al.* (S)-crizotinib reduces gastric cancer growth through oxidative DNA damage and triggers pro-survival akt signal. *Cell Death Dis.* **9**(6), 660 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/03/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM